{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:09:43Z","timestamp":1789474183751,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Lions Cancer research fund Stiftelsen Onkologiska Kliniken Uppsala"},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,3,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>World-wide consensus is lacking regarding patient selection and timing of high-dose chemotherapy (HDCT) with autologous stem-cell support in males with germ cell cancer (GCC). However, within the Swedish and Norwegian Testicular Cancer Group (SWENOTECA) guidelines are harmonised. Our aim was to evaluate survival and toxicity in HDCT-treated GCC-patients within SWENOTECA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In total, 7322 GCC patients were diagnosed between 2011\u20132021 in Sweden and Norway, among which 80 (\u2009~\u20091.1%) patients were treated with HDCT. Indications for HDCT were: Delayed tumour-marker decline during primary\/intensified primary treatment (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200945), progressive disease (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200929), or relapse (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200925). The HDCT-regimen consisted of two cycles of carboplatin\/etoposide.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The 5-year overall survival (5-yr OS) and progression-free survival (5-yr PFS) after HDCT was 55% and 43%, respectively. Indication delayed tumour-marker decline: 5-yr OS:75%, 5-yr PFS:53%, indication progressive disease 5-yr OS:29%, 5-yr PFS:18%, indication relapse 5-yr OS:61%, 5-yr PFS:58%. Four (5%) died due to HDCT-related complications, none within the delayed tumour-marker decline group. Grade 3\u20134 infections were seen in\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200969, 86%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HDCT-treatment according to the SWENOTECA-programme was feasible and associated with promising OS. Early intensification to HDCT for patients with delayed tumour-marker decline during primary-treatment was safe and led to 5-yr OS of 75% with no toxic deaths.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-025-03322-9","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T03:58:17Z","timestamp":1766375897000},"page":"746-753","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["High-dose chemotherapy in male germ cell cancer patients\u2014a study by the SWENOTECA group"],"prefix":"10.1038","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6305-9729","authenticated-orcid":false,"given":"Anna K.","family":"Jansson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Cohn-Cedermark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene F. S.","family":"Negaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torgrim","family":"Tandstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olof","family":"St\u00e5hl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Hedlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5sa","family":"Karlsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hellstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl W.","family":"Langberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8212-0003","authenticated-orcid":false,"given":"Camilla","family":"Sk\u00f6ld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hege S.","family":"Haugnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6158-3041","authenticated-orcid":false,"given":"Ingrid","family":"Glimelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"3322_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3322_CR2","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.eururo.2019.07.002","volume":"76","author":"JK Gurney","year":"2019","unstructured":"Gurney JK, Florio AA, Znaor A, Ferlay J, Laversanne M, Sarfati D, et al. International trends in the incidence of testicular cancer: lessons from 35 years and 41 countries. Eur Urol. 2019;76:615\u201323.","journal-title":"Eur Urol"},{"key":"3322_CR3","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/ijc.32810","volume":"147","author":"A Znaor","year":"2020","unstructured":"Znaor A, Skakkebaek NE, Rajpert-De Meyts E, Laversanne M, Kuli\u0161 T, Gurney J, et al. Testicular cancer incidence predictions in Europe 2010-2035: a rising burden despite population ageing. Int J Cancer. 2020;147:820\u20138.","journal-title":"Int J Cancer"},{"key":"3322_CR4","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1016\/S0140-6736(15)00991-5","volume":"387","author":"E Rajpert-De Meyts","year":"2016","unstructured":"Rajpert-De Meyts E, McGlynn KA, Okamoto K, Jewett MA, Bokemeyer C. Testicular germ cell tumours. Lancet. 2016;387:1762\u201374.","journal-title":"Lancet"},{"key":"3322_CR5","unstructured":"Testikelcancer. \u00c5rsrapport nationellt kvalitetsregister. 2022 [Available from: https:\/\/cancercentrum.se\/download\/18.1d612326194d82b9883294f4\/1740565604061\/testis_arsrapport_2022_final.pdf."},{"key":"3322_CR6","unstructured":"Cancer Registry of Norway. Norwegian Institute of Public Health. Cancer in Norway 2023 - Cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2024."},{"key":"3322_CR7","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1093\/annonc\/mdq575","volume":"22","author":"G Daugaard","year":"2011","unstructured":"Daugaard G, Skoneczna I, Aass N, De Wit R, De Santis M, Dumez H, et al. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol. 2011;22:1054\u201361.","journal-title":"Ann Oncol"},{"key":"3322_CR8","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.eururo.2006.10.035","volume":"51","author":"JP Droz","year":"2007","unstructured":"Droz JP, Kramar A, Biron P, Pico JL, Kerbrat P, P\u00e9ny J, et al. Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial. Eur Urol. 2007;51:739\u201346.","journal-title":"Eur Urol"},{"key":"3322_CR9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1200\/JCO.2005.05.4528","volume":"25","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Nichols CJ, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol. 2007;25:247\u201356.","journal-title":"J Clin Oncol"},{"key":"3322_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41585-022-00683-1","volume":"20","author":"M Chovanec","year":"2023","unstructured":"Chovanec M, Adra N, Abu Zaid M, Abonour R, Einhorn L. High-dose chemotherapy for relapsed testicular germ cell tumours. Nat Rev Urol. 2023;20:217\u201325.","journal-title":"Nat Rev Urol"},{"key":"3322_CR11","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1200\/JCO.2010.32.6678","volume":"29","author":"A Lorch","year":"2011","unstructured":"Lorch A, Bascoul-Mollevi C, Kramar A, Einhorn L, Necchi A, Massard C, et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol. 2011;29:2178\u201384.","journal-title":"J Clin Oncol"},{"key":"3322_CR12","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1200\/JCO.2009.25.1561","volume":"28","author":"DR Feldman","year":"2010","unstructured":"Feldman DR, Sheinfeld J, Bajorin DF, Fischer P, Turkula S, Ishill N, et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol. 2010;28:1706\u201313.","journal-title":"J Clin Oncol"},{"key":"3322_CR13","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1056\/NEJMoa067749","volume":"357","author":"LH Einhorn","year":"2007","unstructured":"Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007;357:340\u20138.","journal-title":"N Engl J Med"},{"key":"3322_CR14","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1200\/JCO.2016.69.5395","volume":"35","author":"N Adra","year":"2017","unstructured":"Adra N, Abonour R, Althouse SK, Albany C, Hanna NH, Einhorn LH. High-dose chemotherapy and autologous peripheral-blood stem-cell transplantation for relapsed metastatic germ cell tumors: the indiana university experience. J Clin Oncol. 2017;35:1096\u2013102.","journal-title":"J Clin Oncol"},{"key":"3322_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3109\/21681805.2015.1059360","volume":"50","author":"T Tandstad","year":"2016","unstructured":"Tandstad T, St\u00e5hl O, H\u00e5kansson U, Wahlqvist R, Klepp O, Cavallin-St\u00e5hl E, et al. The SWENOTECA group: a good example of continuous binational and multidisciplinary collaboration for patients with testicular cancer in Sweden and Norway. Scand J Urol. 2016;50:9\u201313.","journal-title":"Scand J Urol"},{"key":"3322_CR16","doi-asserted-by":"publisher","first-page":"4906","DOI":"10.1200\/JCO.2009.26.8128","volume":"28","author":"A Lorch","year":"2010","unstructured":"Lorch A, Beyer J, Bascoul-Mollevi C, Kramar A, Einhorn LH, Necchi A, et al. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol. 2010;28:4906\u201311.","journal-title":"J Clin Oncol"},{"key":"3322_CR17","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1200\/JCO.2010.29.1278","volume":"29","author":"SE Olofsson","year":"2011","unstructured":"Olofsson SE, Tandstad T, Jerkeman M, Dahl O, St\u00e5hl O, Klepp O, et al. Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group. J Clin Oncol. 2011;29:2032\u20139.","journal-title":"J Clin Oncol"},{"key":"3322_CR18","unstructured":"World Handbook for reporting results of cancer treatment: World Health Organization; 1979 [Available from: https:\/\/iris.who.int\/handle\/10665\/37200."},{"key":"3322_CR19","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1093\/jnci\/85.22.1828","volume":"85","author":"RJ Motzer","year":"1993","unstructured":"Motzer RJ, Mazumdar M, Gulati SC, Bajorin DF, Lyn P, Vlamis V, et al. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst. 1993;85:1828\u201335.","journal-title":"J Natl Cancer Inst"},{"key":"3322_CR20","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.1200\/JCO.2003.09.035","volume":"21","author":"HJ Schmoll","year":"2003","unstructured":"Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Sch\u00f6ffski P, et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I\/II study of the German Testicular Cancer Study Group. J Clin Oncol. 2003;21:4083\u201391.","journal-title":"J Clin Oncol"},{"key":"3322_CR21","doi-asserted-by":"publisher","first-page":"5742","DOI":"10.1200\/JCO.2007.11.9099","volume":"25","author":"JT Hartmann","year":"2007","unstructured":"Hartmann JT, Gauler T, Metzner B, Gerl A, Casper J, Rick O, et al. Phase I\/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group. J Clin Oncol. 2007;25:5742\u20137.","journal-title":"J Clin Oncol"},{"key":"3322_CR22","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1200\/JCO.2001.19.9.2534","volume":"19","author":"M Mazumdar","year":"2001","unstructured":"Mazumdar M, Bajorin DF, Bacik J, Higgins G, Motzer RJ, Bosl GJ. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol. 2001;19:2534\u201341.","journal-title":"J Clin Oncol"},{"key":"3322_CR23","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1200\/JCO.2004.04.008","volume":"22","author":"K Fizazi","year":"2004","unstructured":"Fizazi K, Culine S, Kramar A, Amato RJ, Bouzy J, Chen I, et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol. 2004;22:3868\u201376.","journal-title":"J Clin Oncol"},{"key":"3322_CR24","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1200\/JCO.20.03296","volume":"39","author":"S Gillessen","year":"2021","unstructured":"Gillessen S, Sauv\u00e9 N, Collette L, Daugaard G, de Wit R, Albany C, et al. Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG update consortium. J Clin Oncol. 2021;39:1563\u201374.","journal-title":"J Clin Oncol"},{"key":"3322_CR25","unstructured":"EAU Guidelines. Edn. presented at the EAU Annual Congress Paris 2024. ISBN 978-94-92671-23-3. 2024."},{"key":"3322_CR26","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.6004\/jnccn.2019.0058","volume":"17","author":"T Gilligan","year":"2019","unstructured":"Gilligan T, Lin DW, Aggarwal R, Chism D, Cost N, Derweesh IH, et al. Testicular Cancer, Version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17:1529\u201354.","journal-title":"J Natl Compr Canc Netw"},{"key":"3322_CR27","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.annonc.2022.01.002","volume":"33","author":"J Oldenburg","year":"2022","unstructured":"Oldenburg J, Berney DM, Bokemeyer C, Climent MA, Daugaard G, Gietema JA, et al. Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:362\u201375.","journal-title":"Ann Oncol"},{"key":"3322_CR28","doi-asserted-by":"crossref","unstructured":"International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997;15:594\u2013603.","DOI":"10.1200\/JCO.1997.15.2.594"},{"key":"3322_CR29","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1093\/annonc\/mdi228","volume":"16","author":"JL Pico","year":"2005","unstructured":"Pico JL, Rosti G, Kramar A, Wandt H, Koza V, Salvioni R, et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol. 2005;16:1152\u20139.","journal-title":"Ann Oncol"},{"key":"3322_CR30","doi-asserted-by":"publisher","first-page":"374","DOI":"10.7150\/jca.2.374","volume":"2","author":"DR Feldman","year":"2011","unstructured":"Feldman DR, Huddart R, Hall E, Beyer J, Powles T. Is high dose therapy superior to conventional dose therapy as initial treatment for relapsed germ cell tumors? The TIGER Trial. J Cancer. 2011;2:374\u20137.","journal-title":"J Cancer"},{"key":"3322_CR31","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.clgc.2023.01.004","volume":"21","author":"F Taza","year":"2023","unstructured":"Taza F, Abonour R, Zaid MA, Althouse SK, Anouti B, Akel R, et al. Maintenance oral etoposide after high-dose chemotherapy (HDCT) for patients with relapsed metastatic germ-cell tumors (mGCT). Clin Genitourin Cancer. 2023;21:213\u201320.","journal-title":"Clin Genitourin Cancer"},{"key":"3322_CR32","doi-asserted-by":"publisher","first-page":"TPS429","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS429","volume":"40","author":"R Ashkar","year":"2022","unstructured":"Ashkar R, Adra N, Abonour R, Zaid MIA, Snow CI, Hanna NH, et al. Randomized phase 2 trial of maintenance oral etoposide or observation following high-dose chemotherapy for relapsed metastatic germ cell tumor. J Clin Oncol. 2022;40:TPS429\u2013TPS.","journal-title":"J Clin Oncol"},{"key":"3322_CR33","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen A, Haanen J, Koenecke C, Alsdorf W, Wagner-Drouet E, Borchmann P, et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med. 2023;29:2844\u201353.","journal-title":"Nat Med"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03322-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03322-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03322-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:21:15Z","timestamp":1770974475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03322-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3,5]]}},"alternative-id":["3322"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03322-9","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"12 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HSH: Advisory board Merck, Presenter for Janssen-Cilag and Bayer. IG: Participate in real-world data collection sponsored by Takeda and participated in educational seminars for Johnson and Johnson, Astra Zeneca, Lilly and Takeda with all reimbursement to the Department. All remaining authors have declared no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The studies were ethically approved by the Regional Board of the Ethical Committee in Stockholm according to the Declaration of Helsinki (ethical permit number 2016\/2562-31\/2).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients are included in the SWENOTECA quality-of-care registry after informed written information and oral consent. Patients can opt out if they do not want to participate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}